Tay-sachs disease: Current perspectives from australia

Application of Clinical Genetics

Volumn 8, Issue , 2015, Pages 19-25

  Lew, Raelia M ^a,g   Burnett, Leslie ^b,c,d   Proos, Anné L ^b   Delatycki, Martin B ^e,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e AUSTIN HEALTH   (Australia)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Australia; Genetic screening; Tay Sachs disease

Indexed keywords

AMNIOCENTESIS; ARTICLE; ASHKENAZI JEWISH; AUSTRALIA; CHORION VILLUS SAMPLING; DNA DETERMINATION; ENZYME ASSAY; ETHNIC GROUP; GENE; GENETIC PROCEDURES; GENETIC RISK; GENETIC SCREENING; HEALTH CARE COST; HEALTH PROGRAM; HEXA ENZYME ASSAY; HEXA GENE; HUMAN; INTERNATIONAL RELATIONS; MASSIVELY PARALLEL DNA SEQUENCING; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; TAY SACHS DISEASE;

EID: 84921784012     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/tacg.s49628     Document Type: Article

References (58)

1. Okada S, O’Brien JS. Tay-Sachs disease: generalized absence of a beta-D-N-acetylhexosaminidase component. Science. 1969;165(3894): 698–700.
2. Sandhoff K. Variation of beta-N-acetylhexosaminidase-pattern in Tay-Sachs disease. FEBS Lett. 1969;4(4):351–354.
3. Gravel RA, Clarke JTR, Kaback MM, et al. The GM2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995:2839–2879.
4. Vallance H, Ford J. Carrier testing for autosomal-recessive disorders. Crit Rev Clin Lab Sci. 2003;40(4):473–497.
5. Triggs-Raine BL, Feigenbaum AS, Natowicz M, et al. Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. New Engl J Med. 1990;323(1):6–12.
6. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. Tay-Sachs disease – carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA. 1993;270(19): 2307–2315.
7. Kaback MM. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr. 2000;159 Suppl 3:S192–S195.
8. Rubinstein WD. Judaism in Australia. Australian Govt Pub Service; 1995.
9. Statistics ABo. Reflecting a Nation: Stories from the 2011 Census. Catalogue 2071.0 2012–2013.
10. Rutland SD. The Jews in Australia. Port Melbourne: Cambridge University Press; 2005.
11. Lew R, Burnett L, Proos A. Tay-Sachs disease preconception screening in Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state better than does ancestral origin, although there is an increased risk for c.1421 + 1G. C mutation in individuals with South African heritage. J Community Genet. 2011;2(4):201–209.
12. Burnett L, Proos AL, Chesher D, et al. The Tay-Sachs disease prevention program in Australia: Sydney pilot study. Med J Aust. 1995;163(6):298–300.
13. Barlow-Stewart K, Burnett L, Proos A, et al. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet. 2003;40(4):e45.
14. Kaback MM. Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet. 2001;44:253–265.
15. Ross LF. Heterozygote carrier testing in high schools abroad: what are the lessons for the US? J Law Med Ethics. 2006;34(4):753–764.
16. Godard B, ten Kate L, Evers-Kiebooms G, Aymé S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet. 2003;11 Suppl 2:S49–S87.
17. Mitchell JJ, Capua A, Clow C, Scriver CR. Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet. 1996;59(4): 793–798.
18. Ioannou L, Massie J, Lewis S, et al. Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet. 2010;78(1):21–31.
19. Broide E, Zeigler M, Eckstein J, Bach G. Screening for carriers of Tay-Sachs disease in the ultraorthodox Ashkenazi Jewish community in Israel. Am J Med Genet. 1993;47(2):213–215.
20. Burnett L, Proos AL, Barlow-Stewart K, Aizenberg H. Evaluation of deferred selection of result reporting strategies in community genetic screening for autosomal recessive disorders. Twin Res Hum Genet. 2013;16(4):904.
21. Warren E, Anderson R, Proos AL, Burnett LB, Barlow-Stewart K, Hall J. Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. Genet Med. 2005;7(7):484–494.
22. Gason AA, Sheffield E, Bankier A, et al. Evaluation of a Tay-Sachs disease screening program. Clin Genet. 2003;63(5):386–392.
23. Gason AA, Metcalfe SA, Delatycki MB, et al. Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling. Genet Med. 2005;7(9):626–632.
24. Curd H, Lewis S, Macciocca I, et al. High school Tay-Sachs disease carrier screening: 5 to 11-year follow-up. J Community Genet. 2014;5(2): 139–146.
25. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet. 2001;44:297–310.
26. Frumkin A, Zlotogora J. Genetic screening for reproductive purposes at school: is it a good strategy? Am J Med Genet A. 2008;146A(2): 264–269.
27. Black KI, Gupta S, Rassi A, Kubba A. Why do women experience untimed pregnancies? A review of contraceptive failure rates. Best Pract Res Clin Obstet Gynaecol. 2010;24(4):443–455.
28. Stark Z, Massie J, McClaren B, et al. Current practice and attitudes of Australian obstetricians toward population-based carrier screening for inherited conditions. Twin Res Hum Genet. 2013;16(2):601–607.
29. Gillick v West Norfolk & Wisbech Area Health Authority [1985] UKHL 7 (17 October 1985) [webpage on the Internet]. England: British and Irish Legal Information Institute (BAILII); 1985. Available from: http://www.bailii.org/uk/cases/UKHL/1985/7.html. Accessed October 8, 2014.
30. Department of Health and Community Services v JWB and SMB. 1992.
31. Zlotogora J. Population programs for the detection of couples at risk for severe monogenic genetic diseases. Hum Genet. 2009;126(2): 247–253.
32. Genetics ACo ACOG Committee Opinion No 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol. 2009;114(4):950–953.
33. Lowden JA, Skomorowski MA, Henderson F, Kaback M. Automated assay of hexosaminidases in serum. Clin Chem. 1973;19(12): 1345–1349.
34. Monaghan KG, Feldman GL, Palomaki GE, Spector EB. Ashkenazi Jewish Reproductive Screening Working Group, Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet Med. 2008;10(1):57–72.
35. Schneider A, Nakagawa S, Keep R, et al. Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing. Am J Med Genet A. 2009;149A(11):2444–2447.
36. Kytzia HJ, Sandhoff K. Evidence for two different active sites on human beta-hexosaminidase A. Interaction of GM2 activator protein with beta-hexosaminidase A. J Biol Chem. 1985;260(12): 7568–7572.
37. Fernandes M, Kaplan F, Natowicz M, et al. A new Tay-Sachs disease B1 allele in exon 7 in two compound heterozygotes each with a second novel mutation. Hum Mol Genet. 1992;1(9):759–761.
38. Triggs-Raine BL, Mules EH, Kaback MM, et al. A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening. Am J Hum Genet. 1992;51(4):793–801.
39. D’Souza G, McCann CL, Hedrick J, et al. Tay-Sachs disease carrier screening: a 21-year experience. Genet Test. 2000;4(3):257–263.
40. Arpaia E, Dumbrille-Ross A, Maler T, et al. Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature. 1988; 333(6168):85–86.
41. Myerowitz R, Costigan FC. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J Biol Chem. 1988;263(35):18587–18589.
42. Myerowitz R. Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group. Proc Natl Acad Sci U S A. 1988;85(11):3955–3959.
43. Ohno K, Suzuki K. A splicing defect due to an exon-intron junctional mutation results in abnormal beta-hexosaminidase alpha chain mRNAs in Ashkenazi Jewish patients with Tay-Sachs disease. Biochem Biophys Res Commun. 1988;153(1):463–469.
44. Navon R, Proia RL. The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease. Science. 1989;243(4897):1471–1474.
45. Bach G, Tomczak J, Risch N, Ekstein J. Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am J Med Genet. 2001;99(1):70–75.
46. Brillante R, Yang V, Proos A, Burnett L. PCR analysis of hair root specimens to detect Tay-Sachs disease carriers in Ashkenazi Jews. Clin Chem. 1995;41(2):321–322.
47. Hoffman JD, Greger V, Strovel ET, et al. Next-generation DNA sequencing of HEXA: a step in the right direction for carrier screening. Mol Genet Genomic Med. 2013;1(4):260–268.
48. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011;3(65):65ra64.
49. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–574.
50. Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med. 2012;14(4):393–398.
51. Lew RM, Burnett L, Proos AL, et al. Ashkenazi Jewish population screening for Tay-Sachs disease: The International and Australian experience. J Paediatr Child Health. Epub June 13, 2014.
52. Sekizawa A, Purwosunu Y, Matsuoka R, et al. Recent advances in non-invasive prenatal DNA diagnosis through analysis of maternal blood. J Obstet Gynaecol Res. 2007;33(6):747–764.
53. Hui L, Bianchi DW. Recent advances in the prenatal interrogation of the human fetal genome. Trends Genet. 2013;29(2):84–91.
54. Delatycki MB. Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet. 2008;11(4):422–430.
55. Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A, Fietz MJ. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. Medical J Aust. 2012;197(11): 652–654.
56. Bahar AY, Taylor PJ, Andrews L, et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of US population data. Cancer. 2001;92(2):440–445.
57. Stark Z, Massie J, McClaren B, et al. Current practice and attitudes of Australian obstetricians toward population-based carrier screening for inherited conditions. Twin Res Hum Genet. 2013;16(2):601–607.
58. Chemke J, Zlotogora J. Genetic services in Israel. Eur J Hum Genet. 1997;5 Suppl 2:105–111.